We are live on ! Find out more
TCM

Tekla Capital Management Portfolio holdings

AUM $2.56B
1-Year Est. Return 18.15%
This Fund
S&P 500
This Quarter Est. Return
+13.64%
1 Year Est. Return
+18.15%
3 Year Est. Return
+62.51%
5 Year Est. Return
+140.53%
10 Year Est. Return
+502.91%
AUM
$2.46B
AUM Growth
+$126M
Cap. Flow
-$103M
Cap. Flow %
-4.19%
Top 10 Hldgs %
40.31%
Holding
211
New
10
Increased
47
Reduced
69
Closed
17

Top Buys

Rank Stock Value
1
PFE icon
Pfizer
PFE
+$23.4M
2
MRK icon
Merck
MRK
+$20M
3
WELL icon
Welltower
WELL
+$14.4M
4
CI icon
Cigna
CI
+$9.62M
5
LLY icon
Eli Lilly
LLY
+$9.59M

Top Sells

Rank Stock Value
1
BIIB icon
Biogen
BIIB
+$25.4M
2
JNJ icon
Johnson & Johnson
JNJ
+$18M
3
ALXN
Alexion Pharmaceuticals
ALXN
+$15M
4
ABBV icon
AbbVie
ABBV
+$14.1M
5
VTRS icon
Viatris
VTRS
+$13.4M

Sector Composition

Rank Sector Weight
1 Healthcare 94.43%
2 Real Estate 2.93%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
SYK icon
26
Stryker
SYK
$133B
$24.3M 0.99%
123,050
-37,382
-23% -$6.73M
ISRG icon
27
Intuitive Surgical
ISRG
$126B
$23M 0.93%
120,843
+3,156
+3% +$561K
SGEN
28
DELISTED
Seagen Inc. Common Stock
SGEN
$21.2M 0.86%
289,925
+63,686
+28% +$4.53M
DHR icon
29
Danaher
DHR
$138B
$21M 0.85%
179,274
-56,896
-24% -$5.83M
BMRN icon
30
BioMarin Pharmaceuticals
BMRN
$11.7B
$19.7M 0.8%
222,086
+14,652
+7% +$1.36M
NBIX icon
31
Neurocrine Biosciences
NBIX
$18.7B
$19.5M 0.79%
221,678
+5,384
+2% +$450K
CI icon
32
Cigna
CI
$76.1B
$18.8M 0.76%
116,756
+52,667
+82% +$9.62M
WELL icon
33
Welltower
WELL
$170B
$18.4M 0.75%
237,322
+191,762
+421% +$14.4M
BSX icon
34
Boston Scientific
BSX
$68.4B
$18.2M 0.74%
473,619
+28,628
+6% +$1.09M
SRPT icon
35
Sarepta Therapeutics
SRPT
$1.64B
$17.6M 0.72%
147,847
-43,990
-23% -$5.66M
EXEL icon
36
Exelixis
EXEL
$14.1B
$16.1M 0.66%
678,467
+339,032
+100% +$7.73M
PRAH
37
DELISTED
PRA Health Sciences, Inc.
PRAH
$15.8M 0.64%
143,537
+73,077
+104% +$7.64M
BDX icon
38
Becton Dickinson
BDX
$45.6B
$15.4M 0.63%
63,264
-8,258
-12% -$1.95M
AZN icon
39
AstraZeneca
AZN
$266B
$14.6M 0.59%
180,499
-33,513
-16% -$2.64M
BLUE
40
DELISTED
bluebird bio
BLUE
$14.3M 0.58%
7,027
-572
-8% -$1.01M
IDXX icon
41
Idexx Laboratories
IDXX
$44.1B
$14.2M 0.58%
63,654
+12,079
+23% +$2.49M
TEVA icon
42
Teva Pharmaceuticals
TEVA
$41.2B
$14M 0.57%
890,989
-320,879
-26% -$5.66M
NVO
43
Novo Nordisk
NVO
$228B
$13.2M 0.53%
503,200
-100,600
-17% -$2.47M
OHI icon
44
Omega Healthcare
OHI
$15B
$13M 0.53%
340,266
-39,856
-10% -$1.48M
SAGE
45
DELISTED
Sage Therapeutics
SAGE
$12.7M 0.52%
79,856
-18,588
-19% -$2.69M
AMRN
46
Amarin Corp
AMRN
$298M
$12.7M 0.52%
30,568
-2,135
-7% -$770K
ONC
47
BeOne Medicines Ltd
ONC
$33.4B
$12.5M 0.51%
94,889
+9,134
+11% +$1.23M
ALNY icon
48
Alnylam Pharmaceuticals
ALNY
$27.4B
$12.5M 0.51%
133,458
+7,282
+6% +$609K
HCA icon
49
HCA Healthcare
HCA
$85.7B
$11.7M 0.47%
89,569
+15,234
+20% +$2.05M
BAX icon
50
Baxter International
BAX
$13.8B
$11.2M 0.45%
137,668
-23,565
-15% -$1.72M
1
2
3 4 5

Similar funds

EST
EA Series Trust Havertown, Pennsylvania $2.84B AUM
VIA
Vident Investment Advisory Alpharetta, Georgia $2.9B AUM 24.67% 1-Year Est. Return
AWS
AJ Wealth Strategies New York $2.07B AUM 10.86% 1-Year Est. Return
JP
Jana Partners New York $1.34B AUM 4.95% 1-Year Est. Return
VCM
Vigilant Capital Management Portland, Maine $1.34B AUM 15.33% 1-Year Est. Return
FCFS
First Command Financial Services Fort Worth, Texas $1.06B AUM 10.74% 1-Year Est. Return
FCB
First Command Bank Fort Worth, Texas $1.06B AUM 10.74% 1-Year Est. Return
BWM
BerganKDV Wealth Management Bloomington, Minnesota $1,000M AUM 9.95% 1-Year Est. Return

Tekla Capital Management's Q1 2019 Portfolio in Review

As of Q1 2019, Tekla Capital Management held 211 positions worth $2.46B, up 5.4% from $2.34B the previous quarter. Its ten largest holdings account for 40% of the portfolio.

Tekla Capital Management withdrew a net $103M in Q1 2019, closing 17 positions and reducing 69 holdings. Its most notable exit was Shire pic, an estimated $6.3M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 94% of assets, up from 94% a quarter earlier, followed by Real Estate.

Against the trend, Tekla Capital Management opened a new position in Bio-Techne worth $4.31M.

  • Tekla Capital Management's largest Q1 2019 buy was Bio-Techne: 86,804 shares worth $4.31M.
  • Tekla Capital Management added most to Pfizer in Q1 2019, an estimated $23.4M increase.
  • Tekla Capital Management's biggest Q1 2019 reduction was Biogen, cutting an estimated $25.4M.
  • Tekla Capital Management fully exited Shire pic in Q1 2019, selling an estimated $6.3M.
  • Tekla Capital Management's ten largest holdings make up 40% of its $2.46B portfolio in Q1 2019.
  • Tekla Capital Management opened 10 new positions and closed 17 in Q1 2019.
  • Tekla Capital Management's portfolio value rose 5.4% quarter-over-quarter to $2.46B.

Based on Tekla Capital Management's 13F filing for Q1 2019, filed 14 May 2019.